Pfizer Sues Actavis Over ANDA for Best-Selling Drug Lipitor

Pfizer has filed a patent-infringement lawsuit against Actavis after the Icelandic drugmaker submitted an ANDA to market a generic version of the blockbuster cholesterol drug Lipitor. In its complaint, Pfizer alleges that Actavis’ ANDA would infringe its ’156 patent on Lipitor (atorvastatin). The patent will expire in July 2016, with pediatric exclusivity extending until January 2017. Pfizer is asking that Actavis be barred from selling Lipitor prior to the end of its pediatric exclusivity.
Generic Line